Arpida files iclaprim in EU for infections
This article was originally published in Scrip
Executive Summary
Arpida has filed its lead product, intravenous antibiotic iclaprim, with the EMEAfor the treatment of complicated skin and soft tissue infections (cSSTI). The company filed it with the US FDA in March (Scrip Online, March 20th, 2008) and the agency has set a PDUFA user fee goal date of January 16th, 2009 for the application.
You may also be interested in...
Cerimon receives positive Phase II data on diclofenac patch
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Lilly's Alimta among SMC's September recommendations
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.